Parameter Patients with HTN n=13 Patients without HTN n=20 P
Age [years] 14.8 (6.4-17.8) 14.5 (3.7-18.0) NS
Gender (♂/♀) (n/n, %/%) 7/6 (53.8% / 46.2%) 15/5 (75.0% / 25.0%)
Renal disease (n) (%):
Henoch- Schonlein nephropathy
IgA nephropathy
Membranoproliferative GN
Mesangioproliferative GN
Minimal change disease
FSGS
Other
1 (7.7%)
3 (23.1%)
3 (23.1%)
3 (23.1%)
0 (0.0%)
2 (15.4%)
1 (7.7%)
8 (40.0%)
4 (20.0%)
1 (5.0%)
0 (0.0%)
3 (15.0%)
1 (5.0%)
3 (15.0%)
Age at the onset of renal disease [years] 7.9 (1.5-16.3) 9.6 (0.3-14.8)
Duration of renal disease [months] 22.0 (2.0-144.0) 33.5 (1.0-155.0)
BMI Z-score 0.2 ± 1.4 0.5 ± 1.2
Creatinine [mg/dL] 0.6 (0.3-10.1) 0.6 (0.4-1.3)
Urea [mg/dL] 31.0 (14.0-131.9) 24.0 (10.0-58.0)
Uric acid [mg/dL] 6.5 ± 2.0 5.4 ± 2.0
GFR by Schwartz formula [mL/min/1.73m2] 110.8 (20.8-166.6) 109.9 (50.4-137.3)
Total protein [g/dL] 6.35 (3.8-7.8) 7.0 (3.4-8.1) P<0.05
Albumin [g/dL] 3.6 (2.3-4.8) 4.1 (1.5-4.9) P=0.07
Total cholesterol [mg/dL] 242.7 ± 71.5 191.7 ± 41.3 P<0.05
Triglycerides [mg/dL] 155.4 ± 60.4 129.4 ± 47.6 NS
Calcium [mg/dL] 9.32 ± 1.04 9.68 ± 1.24 P=0.07
Proteinuria n [%] [mg/kg/24h] 8 (54.5%) 80.4 (4.5-184.6) 7 (22.6%) 29.4 (6.7-322.1) NS
Immunosuppressive therapy
Prednisone (n) (%)
Prednisone dose [mg/kg/24h]
Cyclosporin A (n) (%)
Azathioprine (n) (%)
Mycophenolate mofetil (n) (%)
9 (69.2%)
0.96 (0.04-1.43)
3 (23.1%)
2 (15.4%)
2 (15.4%)
14 (70.0%)
0.52 (0.03-1.18)
2 (10.0%)
1 (5.0%)
0 (0.0%)
BMI: Body Mass Index; FSGS: Focal Segmental Glomerulosclerosis; GFR: Glomerular Filtration Rate; GN: Glomerulonephritis.
Table 3: Clinical and biochemical characteristics of children with glomerulopathies with or without concomitant hypertension (HTN).